The Patient Bomb: Sustained Viral Response after Hepatitis C in Cirrhosis.
作者信息
Tato Marinho Rui António Rocha
机构信息
Serviço de Gastrenterologia e Hepatologia, Lisbon, Portugal.
出版信息
GE Port J Gastroenterol. 2020 Apr;27(3):147-148. doi: 10.1159/000504718. Epub 2020 Feb 5.
Abstract
摘要
相似文献
1
The Patient Bomb: Sustained Viral Response after Hepatitis C in Cirrhosis.患者炸弹：肝硬化丙型肝炎后的持续病毒学应答
GE Port J Gastroenterol. 2020 Apr;27(3):147-148. doi: 10.1159/000504718. Epub 2020 Feb 5.
2
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.索磷布韦/维帕他韦治疗 1-6 型丙型肝炎病毒感染合并代偿期肝硬化或中重度纤维化患者的效果
Liver Int. 2018 Mar;38(3):443-450. doi: 10.1111/liv.13534. Epub 2017 Oct 22.
3
An unfortunate failure: multifocal hepatocellular carcinoma in a non-cirrhotic patient with chronic hepatitis C treated with ledipasvir/sofosbuvir.
J Community Hosp Intern Med Perspect. 2018 Jun 12;8(3):167-169. doi: 10.1080/20009666.2018.1473702. eCollection 2018.
4
Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study.索磷布韦联合利巴韦林治疗丙型肝炎基因型 2 患者：一项真实世界、单中心研究。
Arab J Gastroenterol. 2021 Mar;22(1):23-27. doi: 10.1016/j.ajg.2020.09.001. Epub 2020 Nov 19.
5
Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection.丙型肝炎病毒感染患者使用直接抗病毒药物的真实世界经验。
Perm J. 2017;21:16-096. doi: 10.7812/TPP/16-096.
6
Hepatocellular carcinoma in a hepatitis C patient with sustained viral response and no fibrosis.一名丙型肝炎患者出现持续病毒学应答且无肝纤维化，但发生了肝细胞癌。
Ann Hepatol. 2009 Jan-Mar;8(1):64-7.
7
[Effectiveness and safety of sofosbuvir/velpatasvir combination ± ribavirin in the treatment of Chinese adults with chronic hepatitis C virus infection].索磷布韦/维帕他韦联合用药±利巴韦林治疗中国成年慢性丙型肝炎病毒感染者的有效性和安全性
Zhonghua Gan Zang Bing Za Zhi. 2020 Oct 20;28(10):831-837. doi: 10.3760/cma.j.cn501113-20200831-00486.
8
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.在台湾，二甲双胍可降低糖尿病合并慢性丙型肝炎患者抗病毒治疗成功后的肝细胞癌发病率。
J Hepatol. 2023 Feb;78(2):281-292. doi: 10.1016/j.jhep.2022.09.019. Epub 2022 Oct 5.
9
Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.索非布韦和西米普韦用于治疗肝移植后复发性丙型肝炎感染
Exp Clin Transplant. 2017 Jun;15(3):314-319. doi: 10.6002/ect.2015.0289. Epub 2016 Feb 26.
10
Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis.代偿期肝硬化丙型肝炎病毒治疗后骨骼肌质量的改善。
Intern Med. 2021;60(5):745-750. doi: 10.2169/internalmedicine.6029-20. Epub 2021 Mar 1.
引用本文的文献
1
HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development.丙型肝炎病毒蛋白调节宿主细胞微小RNA表达，促进丙型肝炎发病机制及肝细胞癌发展。
Cancers (Basel). 2021 May 19;13(10):2485. doi: 10.3390/cancers13102485.
本文引用的文献
1
Long-Term Follow-Up of Advanced Liver Disease after Sustained Virological Response to Treatment of Hepatitis C with Direct-Acting Antivirals: Outcomes from a Real-World Portuguese Cohort.丙型肝炎直接抗病毒治疗获得持续病毒学应答后晚期肝病的长期随访：来自葡萄牙真实世界队列的结果
GE Port J Gastroenterol. 2020 Apr;27(3):149-159. doi: 10.1159/000503074. Epub 2019 Oct 10.
2
Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.在基线肝硬化或高 FIB-4 评分的患者中，HCV 清除后长达 10 年仍存在肝细胞癌风险增加。
Gastroenterology. 2019 Nov;157(5):1264-1278.e4. doi: 10.1053/j.gastro.2019.07.033. Epub 2019 Jul 26.
3
Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response.肝脂肪变性是慢性丙型肝炎患者持续病毒学应答后不良结局的主要预测因素。
J Viral Hepat. 2019 Nov;26(11):1257-1265. doi: 10.1111/jvh.13167. Epub 2019 Jul 17.
4
Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents.直接作用抗病毒药物治疗的 HCV 患者的肝细胞癌长期风险。
Hepatology. 2020 Jan;71(1):44-55. doi: 10.1002/hep.30823. Epub 2019 Aug 19.
5
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.索磷布韦和维帕他韦治疗近期有注射吸毒史的丙型肝炎病毒感染（SIMPLIFY）：一项开放标签、单臂、4 期、多中心试验。
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6.
6
Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma.比较超声、CT 和 MRI 检测肝细胞癌的敏感性和阳性预测值的 13 年荟萃分析。
Abdom Radiol (NY). 2016 Jan;41(1):71-90. doi: 10.1007/s00261-015-0592-8.
7
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.ABT-450/r-ombitasvir 和 dasabuvir 联合利巴韦林治疗 HCV。
N Engl J Med. 2014 Apr 24;370(17):1604-14. doi: 10.1056/NEJMoa1401561. Epub 2014 Apr 10.
8
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.慢性丙型肝炎合并晚期肝纤维化患者持续病毒学应答与全因死亡率的关系。
JAMA. 2012 Dec 26;308(24):2584-93. doi: 10.1001/jama.2012.144878.
9
Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.非侵入性肝纤维化和肝硬度检测可预测慢性丙型肝炎患者 5 年的转归。
Gastroenterology. 2011 Jun;140(7):1970-9, 1979.e1-3. doi: 10.1053/j.gastro.2011.02.058. Epub 2011 Mar 2.
10
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus.丙型肝炎肝硬化合并糖尿病患者患肝细胞癌的风险增加。
Hepatology. 2008 Jun;47(6):1856-62. doi: 10.1002/hep.22251.
Zotero 插件